Side-by-side · Research reference

ChonlutenvsIGF-1 LR3

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED8/38 cited

BAnimal-StrongHUMAN-REVIEWED10/58 cited

Chonluten

Khavinson Bioregulator · Bronchial Mucosa

BronchialTarget tissue

In vitroEvidence tierAvolio 2022

THP-1Model systemAvolio 2022

Oral · Sublingual · Per Protocol

IGF-1 LR3

IGF-1 Analogue · Research

3–10×Potency vs IGF-I

Low IGFBPBinding affinity

ResearchStatus

Research only · SQ typical in animal models

01Mechanism of Action

Parameter

Chonluten

IGF-1 LR3

Primary target

Bronchial epithelial cells and respiratory mucosa tissue complexes

IGF-1 receptor (IGF-1R)McTavish 2009

Pathway

Bioregulatory peptide interaction → modulation of proliferative and inflammatory pathways in monocyte/macrophage populationsAvolio 2022

IGF-1R → IRS-1 → PI3K/Akt → Cell proliferation, protein synthesis, anti-apoptosisMuhlbradt 2009

Downstream effect

Regulation of proliferative activity and inflammatory mediator production in respiratory-associated immune cellsAvolio 2022

Enhanced cell proliferation, muscle anabolism, inhibition of apoptosis, increased telomerase activity

Feedback intact?

—

No — exogenous IGF analogue bypasses GH-mediated regulation

Origin

Khavinson bioregulator peptide complex derived from bronchial mucosa tissue extract methodology

Synthetic 83-AA analogue: 13-AA N-terminal extension + Arg substitution at position 3

Antibody development

—

02Dosage Protocols

Parameter

Chonluten

IGF-1 LR3

Typical protocol dose

10–20 mg / day

Russian bioregulator tradition dosing; not standardized in Western literature.

—

Frequency

Once or twice daily

—

Route

Oral (capsule) or sublingual

Sublingual claimed for enhanced bioavailability; not validated.

—

Evidence basis

In vitro mechanistic

Animal / in vitro only

Duration

10–30 days per cycle

Traditional Khavinson protocol; cyclic administration common.

—

Clinical validation

None (PubMed indexed)

—

Research dose (animal models)

—

Variable by protocol and species

In vivo murine atherosclerosis studies used sustained delivery.

In vitro typical concentration

—

10–1000 ng/mLThomas 2007

Dose-dependent effects on follicle growth and estradiol production.

Half-maximal stimulation

—

0.6 nM LR3 vs 1.5 nM native IGF-1Price 2004

2.5-fold greater potency in lung fibroblast proliferation.

Human use

—

Not FDA-approved; no published human trials

03Metabolic / Fat Loss Evidence

Parameter

Chonluten

IGF-1 LR3

Mechanism

—

IGF-1R activation → lipolytic signaling; secondary to anabolic effects

Direct lipolytic evidence

—

Minimal — primarily anabolic/anti-apoptotic in literature

Atherosclerotic plaque effects

—

Reduced stenosis and core size in ApoE-KO micevon 2011

Plaque stabilization via vSMC phenotype modulation, not direct fat loss.

Human data

—

None published

04Side Effects & Safety

Parameter

Chonluten

IGF-1 LR3

Documented adverse events

No published safety data in PubMed-indexed literature

—

Theoretical risks

Peptide hypersensitivity, GI intolerance (uncharacterized)

—

Drug interactions

Unknown — no pharmacokinetic studies available

—

Pregnancy / lactation

No data — avoid

—

Hypoglycemia risk

—

Theoretical — IGF-1 analogues can lower blood glucose

Excessive cell proliferation

—

Mitogenic signaling; theoretical tumor promotion risk

Telomerase activation

—

2–10-fold increase in prostate cancer cells (PC-3, DU-145, LAPC-4)Wetterau 2003

Critically involved in cancer cell immortalization.

Oocyte degeneration

—

Increased oocyte degeneration at high doses (≥1000 ng/mL) in bovine folliclesThomas 2007

Unregulated anabolism

—

Bypasses physiological GH/IGF-1 feedback; no pulsatility control

Unknown human safety profile

—

No published human trials; safety data absent

Absolute Contraindications

Chonluten

·Known hypersensitivity to peptide components

IGF-1 LR3

·Active malignancy or history of cancer
·Not approved for human use

Relative Contraindications

Chonluten

·Pregnancy and lactation (insufficient data)
·Active malignancy (theoretical bioregulator concern)

IGF-1 LR3

·Diabetes or glucose intolerance
·Family history of cancer

05Administration Protocol

Parameter

Chonluten

IGF-1 LR3

1. Preparation

Typically supplied as capsules or sublingual tablets. No reconstitution required. Store in cool, dry place away from light.

IGF-1 LR3 is not FDA-approved for human use. All administration data derives from animal or in vitro studies.

2. Oral route

Swallow capsule with water, 20–30 minutes before meals or as directed. Traditional Khavinson protocol emphasizes empty stomach for absorption.

Subcutaneous or intraperitoneal injection in animal models. In vitro: added directly to culture medium at concentrations of 10–1000 ng/mL.Thomas 2007

3. Sublingual route

Place tablet under tongue, allow dissolution for 1–2 minutes. Avoid swallowing immediately. Claimed to bypass first-pass metabolism.

Lyophilised powder reconstituted in sterile water or buffered saline per manufacturer protocol. Store at 2–8 °C after reconstitution.

4. Timing

Morning dose preferred; may split into twice-daily if higher dose used. Consistency emphasized in bioregulator protocols.

Enhanced stability vs native IGF-1 due to reduced IGFBP binding; exact half-life in vivo not fully characterized in humans.

5. Cycle protocol

10–30 day cycles common in Russian tradition. Rest period of 1–3 months between cycles often recommended, though no published evidence for this approach.

—

06Stack Synergy

Chonluten

— no documented stacks

IGF-1 LR3

+ GHRP-6

Multi-pathway

View GHRP-6 →

GHRP-6 stimulates endogenous GH release, which drives hepatic IGF-1 synthesis. IGF-1 LR3 provides exogenous, IGFBP-resistant IGF signaling. Combining upstream GH stimulation with downstream IGF receptor activation creates a dual-pathway anabolic effect. However, this bypasses natural feedback and carries compounded mitogenic risk.

GHRP-6: 100–200 mcg SQ · 2–3× daily
IGF-1 LR3: Research doses variable · post-workout typical in animal models
Note: Research context only — no human protocols exist
Primary benefit: Theoretical maximal anabolic signaling (GH + IGF axes)

+ Ipamorelin

Multi-pathway

View Ipamorelin →

Ipamorelin (selective GHRP) stimulates pulsatile GH release without cortisol/prolactin elevation. IGF-1 LR3 directly activates IGF-1R independent of GH. This stack targets both upstream (GH secretion) and downstream (IGF receptor) nodes but eliminates physiological feedback, raising safety concerns around unchecked proliferation.

Ipamorelin: 200–300 mcg SQ · evening
IGF-1 LR3: Research doses only · timing variable
Caution: No human data; animal/in vitro only
Primary benefit: Dual-axis anabolic signaling (theoretical)